All studies were approved by the Institutional Animal Care and Use Committee. For xenograft experiments, 5×106 cells (SW480 CCAR2 CRISPR/Cas9 knockout or vector controls) were injected into either flank of male athymic nude mice (Envigo, Somerset, NJ). After 10 d, animals were randomized as follows (n=5 mice/group): SFN, 100 mg/kg body weight (BW) via daily oral gavage; JQ1, 50 mg/kg BW, twice weekly i.p. injection; SFN+JQ1, at doses of the individual compounds, or vehicle. Tumor volumes were measured twice/week using calipers. In rat experiments, Pirc males (29 (link)) at 5 months of age were assigned to study groups (3–4/group), and 2 months later occluding colon polyps were resected (36 (link)). Rats were then treated for 5 weeks with test agents, as follows: SFN, 400 parts per million (p.p.m.) in AIN93 diet; JQ1, 12.5 mg/kg BW via twice weekly i.p. injection; SFN+JQ1, at the doses of the individual compounds, or vehicle. The study was terminated 2 months after polypectomy, and GI lesions were enumerated prior to IB and RNA-seq, as reported (28 (link)). To our knowledge, this is the first report to examine secondary prevention in a murine model of FAP, following surgical intervention.